Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Research Applications & Key Findings Growth Hormone Secretion Research Pituitary Function Studies Extensive research has examined the growth hormone secretagogue properties of the CJC-1295 + Ipamorelin combination across multiple species: Dose-dependent GH release demonstrated in rat anterior pituitary cell cultures with picomolar to micromolar peptide concentrations 2- to 10-fold increases in plasma growth hormone levels sustained for 6 days in human subjects following single CJC-1295 dose Preserved pulsatile secretion with ipamorelin addition, preventing continuous non-physiological stimulation Selective action on growth hormone release without affecting prolactin, ACTH, cortisol, FSH, or TSH levels Human trials with healthy subjects aged 21-61 years demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels that were safe and well-tolerated at doses of 30-60 mcg/kg
Galanakis, C
2025 | 6:32AM (IST) Manufacturer details P
The current product page lists C 14 H 24 CuN 6 O 4 and approximately 403.91 g/mol
NHS Access Pathway: Consult your GP to discuss whether GLP-1 treatment is appropriate for your condition
10.1124/jpet.103.064261 40 IhediohaJ
US$ 27.16
US$ 26.87
US$ 21.35
US$ 25.91
US$ 21.58
